Novo Nordisk facing pressure as study finds $1k drug can be made for $5
A study suggesting that Novo Nordisk’s blockbuster weight-loss and diabetes drug semaglutide (Ozempic/Wegovy) could be manufactured for about $5 a month, versus list prices near $1,000, has reignited debate over drug pricing and pharmaceutical profits. Commenters weigh the need to recoup massive R&D and regulatory costs against accusations of price gouging, pointing to U.S. healthcare structures, patent games, and marketing-heavy budgets as key drivers of high prices. Many see GLP‑1 drugs as potentially transformative for obesity and related conditions, but argue over whether access should be expanded through regulation, public funding, or alternative models like single‑payer purchasing and publicly run drug development.
Real‑world use, benefits, and risks
- Ozempic/Wegovy are described as extremely popular, driven by social media, celebrity use, and visible rapid weight loss (30–40+ lbs in months).
- Many see big benefits: obesity reduction, potential reductions in addiction-like behaviors (alcohol, gambling), and better metabolic control.
- Side effects discussed include GI issues (diarrhea, possible gastric paralysis), pancreatitis, thyroid cancer concerns, and possible vision loss.
- Commenters stress that obesity itself is deadly, so risk–benefit tradeoffs may still favor use.
Mechanism and long‑term uncertainty
- Drugs are GLP‑1 agonists, affecting insulin response and central nervous system processes controlling appetite and cravings.
- Concerns about long‑term effects: muscle and bone loss, cardiac/pulmonary issues, pancreatic or insulin dysfunction, and incomplete long‑term cancer data.
- Some argue the body’s complex feedback loops mean side effects are inevitable; others suggest this may still be a net positive breakthrough.
Pricing, cost, and patents
- The “$5 to make vs ~$1,000 to sell” is framed as marginal manufacturing cost vs total cost (R&D, failed trials, regulation, overhead).
- Estimates cited: $300M–$2B to bring a drug to market with ~12% success; some say prices must cover many failures.
- Others argue pharma profits and marketing spend are high, so “R&D justification” is overstated.
- Paper’s modeled prices assume 10–50% profit margins; some say such margins might not sustain innovation under current regulation.
- There is broad agreement prices are far lower outside the US; reasons debated (US subsidizing R&D vs rent‑seeking and weak bargaining).
Health system and ethics debates
- Strong debate over whether lifesaving or transformative drugs should be high‑profit products vs publicly funded, low‑price utilities.
- Some want pharma highly profitable to attract talent and innovation; others liken profit from medicine to profiting from weapons.
- Single‑payer and price regulation (e.g., insulin caps) are cited as levers; US insurance middlemen and opaque pricing are heavily criticized.
- Proposals range from full public funding and production of drugs to value‑based pricing and better antitrust/patent enforcement.
Access, scarcity, and practical issues
- Current supply is constrained; richer patients and countries get priority.
- Non‑diabetics often use Ozempic off‑label or instead of Wegovy due to availability, insurance coverage, and pen dosing tricks to stretch expensive pens.
- Some fear that widespread reliance on such drugs could have evolutionary or social consequences; others dismiss this as speculative or “dysgenic” reasoning.